KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Acquisitions (2016)

Travere Therapeutics (TVTX) has disclosed Acquisitions for 3 consecutive years, with $115000.0 as the latest value for Q4 2016.

  • For the quarter ending Q4 2016, Acquisitions changed N/A year-over-year to $115000.0, compared with a TTM value of $115000.0 through Dec 2017, down 81.3%, and an annual FY2020 reading of $95.3 million, changed N/A over the prior year.
  • Acquisitions was $115000.0 for Q4 2016 at Travere Therapeutics, down from $500000.0 in the prior quarter.
  • Across five years, Acquisitions topped out at $33.4 million in Q1 2015 and bottomed at $115000.0 in Q4 2016.
  • Average Acquisitions over 3 years is $15.8 million, with a median of $14.8 million recorded in 2014.
  • Peak annual rise in Acquisitions hit 14.68% in 2015, while the deepest fall reached 14.68% in 2015.
  • Year by year, Acquisitions stood at $29.2 million in 2014, then rose by 14.68% to $33.4 million in 2015, then tumbled by 99.66% to $115000.0 in 2016.
  • Business Quant data shows Acquisitions for TVTX at $115000.0 in Q4 2016, $500000.0 in Q2 2016, and $33.4 million in Q1 2015.